1. Scrip
  2. >>Business

Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL

 
• By Alaric DeArment

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept
Novartis is aiming for adherence, access and affordability to ensure Leqvio's success in the US • Source: Shutterstock

In spite of its delayed timeline for US market entry, Novartis AG is hoping its strategy around inclisiran in atherosclerotic cardiovascular disease (ASCVD) – focusing on adherence, access and affordability – can ensure sufficient uptake of the twice-yearly PCSK9 inhibitor if it wins Food and Drug Administration approval.

The company has been busy at work developing a buy-and-bill infrastructure, as well as a network of injection centers, and focusing on the health care systems that account for the majority of ASCVD diagnoses and prescriptions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.